Cancer Treatment Reviews
Volume 27, Issue 6 , Pages 375-402 , December 2001

Chemo-immunotherapy and chemo-adoptive immunotherapy of cancer

  • G.G Gomez

      Affiliations

    • Department of Pathology, University of Colorado Health Sciences Center, Denver, Colorado, USA
    • ,
  • R.B Hutchison

      Affiliations

    • Department of Immunology, University of Colorado Health Sciences Center, Denver, Colorado, USA
    • ,
  • C.A Kruse

      Affiliations

    • Department of Pathology, University of Colorado Health Sciences Center, Denver, Colorado, USA
    • Department of Immunology, University of Colorado Health Sciences Center, Denver, Colorado, USA

References 

  1. Kelsen DP. Adjuvant and neoadjuvant therapy for gastric cancer. Seminars in Oncology. 1996;23:379–389
  2. Bailar J. In:  Freeman HP,  Pitot HC,  Visco FM editor. Observations on some recent trends in cancer. Bethesda: National Institutes of Health; 1993;p. 197–213
  3. Rosenberg SA. The immunotherapy and gene therapy of cancer. J Clin Oncol. 1992;10:180–199
  4. Schirrmacher V. Biotherapy of Cancer: Perspectives of immunotherapy and gene therapy. J Cancer Res Clin Oncol. 1995;121:443–451
  5. Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten original cases. Am J Med Sciences. 1893;May issue:487–511
  6. Coley WB. A preliminary note on the treatment of inoperable sarcoma by the toxic products of erysipelas. Post-Graduate. 1897;8:278–286
  7. Hericourt J, Richet C. De la serotherapie dans le traitement du cancer. C R Hebd Acad Sci (Paris). 1895;120:567–569
  8. Hericourt J, Richet C. Traitement d'un cas de sarcome par la serotherapie. C R Acad Sci (Paris). 1895;120:948–950
  9. Robb RJ, Kutney RM, Chowdry V. Purification and partial sequence of human T cell growth factor. Proc Nat Acad Sci, USA. 1983;80:5590–5595
  10. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. The lymphokine activated killer cell phenomena: lysis of NK resistent fresh solid tumor cells by IL-2 activated autologous human peripheral blood lymphocytes. J Exp Med. 1982;155:1823–1841
  11. Herberman RB, Hiserodt J, Vujanovic N. Lymphokine activated killer cell activity: characteristics of effector cells and their progenitors in blood and spleen. Immunol Today. 1987;8:178–181
  12. Ehrke MH, Cohn SA, Mihich E. Selective effects of adriamycin on murine host defense systems. Immunol Rev. 1982;65:55
  13. Berd D, Mastrangelo MJ. Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T-cells. Cancer Research. 1988;48:1671–1675
  14. Hoon DB, Foshag LJ, Nizze AS, Bohman R, Morton DL. Suppressor-cell activity in a randomized trial of patients receiving active specific immunotherapy with melanoma cell vaccine and low dosages of cyclophosphamide. Cancer Research. 1990;50:5358–5364
  15. Sahasrabudhe DM, deKernion JB, Pontes JE. Specific immunotherapy with suppressor function inhibition for metastatic renal-cell carcinoma. J Biol Resp Mod. 1986;5:581–594
  16. Hengst J CD, Mokyr MB, Dray S. Importance of timing in cyclophosphamide therapy of MOPC-315 tumor bearing mice. Cancer Research. 1980;40:2135–2141
  17. Hengst J CD, Mokyr MB, Dray S. Cooperation between cyclophosphamide tumoricidal activity and host antitumor immunity in the cure of mice bearing large MOPC-315 tumors. Cancer Research. 1981;41:2163
  18. Proietti E, Greco G, Garrone B. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice. J Clin Invest. 1998;101:429–441
  19. Isaacs JT. Relationship between tumor size and curability of prostatic cancer by combined chemo-hormonal therapy in rats. Cancer Research. 1989;49:6290–6294
  20. Stockman GD, Heim LR, South MA, Trentin JJ. Differential effects of cyclophosphamide on the B and T cell compartments of adult mice. J Immunol. 1973;110:277–282
  21. North RJ. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med. 1982;55:1063–1074
  22. Berd D, Mastrangelo MJ. Effect of low dose cyclophosphamide on the immune system of cancer patients: Reduction of T-suppressor function without depletion of the CD8+ subset. Cancer Research. 1987;47:3317–3321
  23. Awwad M, North RJ. Cyclophosphamide (CY)-facilitated adoptive immunotherapy of a CY-resistant tumour. Evidence that CY permits the expression of adoptive T-cell mediated immunity by removing suppressor T-cells rather than reducing tumour burden. Immunology. 1988;65:87–92
  24. Greenberg PD, Kern DE, Cheever MA. Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt 1+,2- T-cells: tumor eradication does not require participation of cytotoxic T cells. J Exp Med. 1985;161:1122–1134
  25. Greenberg PD. Therapy of murine leukemia with cyclophosphamide and immune Lyt-2+ cells: cytolytic T-cells can mediate eradication of disseminated leukemia. J Immunol. 1986;136:1917–1922
  26. Bookman MA, Swerdlow R, Matis LA. Adoptive chemoimmunotherapy of murine leukemia with helper T-lymphocyte clones. J Immunol. 1987;139:3166–3170
  27. Kruse CA, Mitchell DH, Kleinschmidt-DeMasters BK. Systemic chemotherapy combined with local adoptive immunotherapy cures rats bearing 9L gliosarcoma. J Neurooncol. 1993;15:97–112
  28. Goldfarb RH, Ohashi M, Brunson KW. Augmentation of IL-2 activated natural killer cell adoptive immunotherapy with cyclophosphamide. Anticancer Research. 1998;18:1441–1446
  29. Wasserman J, Petrini B, Blomgren H. Radiosensitivity of T-lymphocytes subpopulations. J Clin Lab Immuno. 1982;7:139–142
  30. Hersh EM, Patt YZ, Murphy SG. Radiosensitive, thymic-hormone sensitive peripheral blood suppressor cell activity in cancer patients. Cancer Research. 1980;40:3134–3141
  31. Waymack JP, Guzman RF, Burleson DG. Effect of prostaglandin E in multiple experimental models. VI. Effect on T-cell subsets. Prostaglandins. 1989;38:345–353
  32. Kahn MM, Sansoni P, Engleman EG, Melmon KL. Pharmacologic effects of autocoids on subsets of T cells. J Clin Invest. 1985;75:1578–1583
  33. Lee JH, Klein HG. Mononuclear cell adoptive immunotherapy. Transfusion Medicine I.. Bethesda: National Institutes of Health; 1994; p. 1203–21
  34. Goldfarb RH, Brunson KW. Therapeutic agents for treatment of established metastases and inhibitors of metastatic spread: preclinical and clinical progress. Curr Opin Oncol. 1992;4:1130–1141
  35. Greenspan EM, Erlich R. Levamisole and the new era of chemoimmunotherapy. Cancer Invest. 1991;9:111–124
  36. Rosenberg SA, Lotze MT. Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes. Ann Rev Immunol. 1986;4:681–709
  37. Gold JE, Ross SD, Krellenstein DJ. Adoptive transfer of ex vivo-activated memory T-cells with or without cyclophosphamide for advanced metastatic melanoma: results in 36 patients. Eur J Cancer. 1995;31A:698–708
  38. Kawata A, Une Y, Hosokawa M. Adjuvant chemoimmunotherapy for hepatocellular carcinoma patients: adriamycin, interleukin-2, and lymphokine-activated killer cells versus adriamycin alone. Am J Clin Oncol. 1995;18:257–262
  39. Uchino J, Une Y, Kawata A, Wakisaka Y, Hosokawa M. Postoperative chemoimunotherapy for the treatment of liver cancer. Sem Surg Oncol. 1993;9:332–336
  40. Gold JE, Malamud SC, LaRosa F, Seder R, Osband ME. Adoptive chemoimmunotherapy for the treatment of relapsed and refractory solid tumors using ex vivo activated memory T cells (autolymphocyte therapy) and cyclophosphamide. J Immunother. 1993;13:213–221
  41. Curti BD, Ochoa AC, Powers GC. Phase I trial of anti-CD3-stimulated CD4+ T cells, infusional interleukin-2, and cyclophosphamide in patients with advanced cancer. J Clinical Oncol. 1998;16:2752–2760
  42. Ueta E, Osaki T, Yamamoto T, Yoneda K. Induction of differentiation in maxillary adenoid cystic carcinomas by adoptive immunotherapy in combination with chemoradiotherapy. Oral Oncology. 1998;34:105–111
  43. Suzuki M, Kimura H, Iwai N, Fujisawa T. Intermittent adjuvant chemo-immunotherapy after resection of non-small cell lung cancer with multilevel mediastinal lymph node metastasis. Oncology Reports. 2000;7:545–549
  44. Tomita Y, Katagiri A, Saito K. Adoptive immunotherapy of patients with metastatic renal cell cancer using lymphokine-activated killer cells, interleukin-2 and cyclophosphamide: long-term results. Int J Urology. 1998;5:16–21
  45. Murakami K, Tanimura H, Yamaue H. Clinical effect of immunochemotherapy for a patient with advanced gallbladder cancer: report of a case. Surgery Today. 1998;28:923–928
  46. Tani M, Tanimura H, Yamaue H. Successful immunochemotherapy for patients with malignant mesothelioma: report of two cases. Surgery Today. 1998;28:647–651
  47. Martin DS, Balis ME, Fisher B. Role of murine tumor models in cancer treatment research. Cancer Research. 1986;46:2189–2192
  48. Gold JE, Zachary DT, Osband ME. Adoptively transferred ex vivo activated memory T cells with cyclophosphamide: effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma. Clin Immunol Immunopathol. 1994;73:115–122
  49. Gold JE, Zachary DT, Osband ME. Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic melanoma and carcinoma. Int J Cancer. 1995;61:580–586
  50. Saxton ML, Longo DL, Wetzel HE. Adoptive transfer of anti-CD3-activated CD4+ T cells plus cyclophosphamide and liposome-encapsulated interleukin-2 cure murine MC-38 and 3LL tumors and establish tumor-specific immunity. Blood. 1997;89:2529–2536
  51. O'Conner R, Cesano A, Lange B. Growth factor requirements of childhood acute T-lymphoblastic leukemia: correlation between presence of chromosomal abnormalities and ability to grow permanently in vitro. Blood. 1991;77:1534–1545
  52. Cesano A, Santoli D. Inducible expression of granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-alpha, and interferon-gamma in two human cytotoxic leukemic T-cell lines. In Vitro Cell Dev Biol. 1992;28A:657–662
  53. Cesano A, Vissoneau S, Cioe L, Clark SC, Santoli D. Effects of lethal irradiation and cyclosporin A treatment on the growth and tumoricidal activity of a T cell clone potentially useful in cancer therapy. Cancer Immunol Immunother. 1995;40:139–151
  54. Cesano A, Visonneau S, Rovera G, Santoli D. Synergistic effects of adriamycin and TALL-104 cell therapy against a human gastric carcinoma in vivo. Anticancer Research. 1997;17:1887–1892
  55. Mokyr MB, Barker E, Weiskirch LM, Takesue BY, Pyle JM. Importance of Lyt2+ T-cells in the curative effectiveness of a low dose of melphalan for mice bearing a large MOPC-315 tumor. Cancer Research. 1989;49:4597
  56. Weiskirch LM, Barker E, Mokyr MB. Eradication of a large MOPC-315 tumor in athymic nude mice by chemoimmunotherapy with Lyt2+ splenic T cells from melphalan-treated BALB/c mice bearing a large MOPC-315 tumor. Cancer Immunol Immunother. 1990;31:129–138
  57. Laude M, Siessmann KL, Mokyr MB, Dray S. Advantages of adoptive chemoimmunotherapy with polyethylene glycol-cultured, antigen-activated, tumor-infiltrated spleen cells for the complete eradication of lethal MOPC-315 plasmacytomas. Cancer Research. 1991;51:4516–4522
  58. Weiskirch LM, Mokyr MB. Some approaches to improve the therapeutic effectiveness of adoptive chemoimmunotherapy with spleen cells from melphalan-treated BALB/c mice bearing a large MOPC-315 tumor. Int J Cancer. 1992;51:84–92
  59. Mokyr MB, Prokhorava A, Rubin M, Bluestone JA. Insight into the mechanism of TCR-V beta 8+/CD8+ T cell-mediated MOPC-315 tumor eradication. J Immunol. 1994;153:3123–3134
  60. Laude M, Russo KL, Mokyr MB, Dray S. Cure of mice bearing a late-stage, highly metastatic, drug-resistant tumor by adoptive chemoimmunotherapy. Cancer Immunol Immunother. 1993;36:229–236
  61. Laude M, Russo KL, Mokyr MB, Dray S. Two tumor models of curative adoptive chemoimmunotherapy using tumor-infiltrated spleen cells with potent antitumor cytotoxicity stimulated by antigen-sharing tumors. Cancer Immunol Immunother. 1993;37:89–96
  62. Ghanta VK, Hiramoto NS, Soong SJ, Miller DM, Hiramoto RN. A multiple modality approach combining the effect of conditioning with adoptive chemoimmunotherapy. Int J Neurosci. 1993;71:251–265
  63. Eggermont AM, Sugarbaker PH. Immunogenicity of the tumor determines the outcome of immunotherapy with interleukin-2, ABPP, and cyclophosphamide of micro- and macrometastatic intraperitoneal tumor. Cancer Det Prev. 1990;14:483–490
  64. Zeidner NS, Mathiason-DuBard CK, Hoover EA. Reversal of feline leukemia virus infection by adoptive transfer of lectin/interleukin-2 activated lymphocytes, interferon-alpha, and zidovudine. J Immunother. 1993;14:22–32
  65. Zeidner NS, Mathiason-DuBard CK, Hoover EA. Reversal of feline leukemia virus infection by adoptive transfer of activated T lymphocytes, interferon-alpha, and ziduvudine. Sem Vet Med Surg (Sm Animal). 1995;10:256–266
  66. Zeidner NS, Rose LM, Mathiason-DuBard CK. Zidovudine in combination with alpha interferon and interleukin-2 as prophylactic therapy for FeLV-induced immunodeficiency syndrome (FeLV-FAIDS). J Acq Immune Def Synd. 1990;3:787–796
  67. Vierboom MP, Bos GM, Ooms M, Offringa R, Melief CJ. Cyclophosphamide enhances anti-tumor effect of wild-type p53-specific CTL. Int J Cancer. 2000;87:253–260
  68. Evans R, Fuller JA, Christianson G, Krupke DM, Troutt AB. IL-15 mediates anti-tumor effects after cyclophosphamide injection of tumor-bearing mice and enhances adoptive immunotherapy: the potential role of NK cell subpopulations. Cellular Immunology. 1997;179:66–73
  69. Cao X, Wang J, Zhang W. Treatment of human hepatocellular carcinoma by fibroblast-mediated human interferon-alpha gene therapy in combination with adoptive chemoimmunotherapy. J Cancer Res Clin Oncol. 1995;121:457–462
  70. Quintieri L, Rosato A, Amboldi N. Delivery of methoxymorpholinyl doxorubicin by interleukin 2-activated NK cells: effect in mice bearing hepatic metastases. British J Cancer. 1999;79:1067–1073
  71. Mandruzzato S, Rosato A, Bronte V. Adoptive transfer of lymphokine-activated killer cells loaded with 4′-deoxy-4′-iododoxorubicin: therapeutic effect in mice bearing lung metastases. Cancer Research. 1994;54:1016–1020
  72. Goldfarb RH, Koelemij R, Muirhead KA. A novel drug delivery system using IL-2 activated NK cells and Zyn-linked doxorubicin. In Vivo. 2000;14:101–104
  73. Kruse CA, Lillehei KO, Mitchell DH, Kleinschmidt-DeMasters BK, Bellgrau D. Analysis of interleukin 2 and various effector cell populations in adoptive immunotherapy of 9L gliosarcoma: allogeneic cytotoxic T lymphocytes prevent tumor take. Proc Nat Acad Sci, USA. 1990;87:9577–9581
  74. Legha SS. The role of interferon alpha in the treatment of metastatic melanoma. Sem Oncol. 1997;24:S24–S31
  75. Garbe C. Chemotherapy and chemoimmunotherapy in disseminated malignant melanoma. Melanoma Res. 1993;3:291–299
  76. Hernberg M, Muhonen T, Turunen JP, Hahka-Kemppinen M, Pyrhonen S. The CD4+/CD8+ ratio as a prognostic factor in patients with metastatic melanoma receiving chemoimmunotherapy. J Clin Oncol. 1996;14:1690–1696
  77. Dummer R, Gore ME, Hancock BW. A multicenter phase II clinical trial using dacarbazine and continuous infusion interleukin-2 for metastatic melanoma. Clinical data and immunomonitoring. Cancer. 1995;75:1038–1044
  78. Terheyden P, Becker JC, Kampgen E, Brocker EB. Sequential interferon-alpha 2b, interleukin-2 and fotemustine for patients with metastatic melanoma. Melanoma Research. 2000;10:475–482
  79. Naglieri E, Procacci A, Galetta D. Cisplatin, interleukin-2, interferon-alpha and tamoxifen in metastatic melanoma. A phase II study. J Chemother. 1999;11:150–155
  80. Thompson JA, Gold PJ, Fefer A. Outpatient chemoimmunotherapy for the treatment of metastatic melanoma. Sem Oncol. 1997;24:S44–S48
  81. Heywood GR, Rosenberg SA, Weber JS. Hypersensitivity reactions to chemotherapy agents in patients receiving chemoimmunotherapy with high-dose interleukin-2. J Nat Cancer Inst. 1995;87:915–922
  82. Atzpodien J, Lopez Hanninen E, Kirchner H. Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine, cisplatin, carmustine and tamoxifen. Eur J Cancer. 1995;31A:876–881
  83. Atkins MB, O'Boyle KR, Sosman JA. Multi-institutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma. J Clin Oncol. 1994;12:1553–1560
  84. Richards JM, Mehta N, Ramming K, Skosey P. Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol. 1992;10:1338–1343
  85. Hoffmann R, Muller I, Neuber K. Risk and outcome in metastatic malignant melanoma patients receiving DTIC, cisplatin, BCNU and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha2a. British J Cancer. 1998;78:1076–1080
  86. Khayat D, Borel C, Tourani JM. Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon-alpha-2a for metastatic melanoma. J. Clin Oncol. 1993;11:2173–2180
  87. Khayat D, Antoine E, Rixe O. Chemoimmunotherapy of metastatic malignant melanoma. The Salpetriere Hospital (SOMPS) experience. Eur J Cancer. 1993;29A:S2–S5
  88. Castel T, Estape J, Vinolas N. Adjuvant treatment in stage I and II malignant melanoma: a randomized trial between chemoimmunotherapy and immunotherapy. Dermatologica. 1991;183:25–30
  89. Guida M, Latorre A, Selvaggi FP, DiTonno P, Lorusso V, Mastria A, et al. Subcutaneous recombinant interleukin-2 plus alpha interferon and vinblastine in metastatic renal cell carcinoma: A phase II study. Int J Oncol. 1997;10:487–491
  90. Naglieri E, Gebbia V, Durini E. Standard interleukin-2 (IL-2) and interferon-alpha immunotherapy versus an IL-2 and 4-epirubicin immuno-chemotherapeutic association in metastatic renal cell carcinoma. Anticancer Research. 1998;18:2021–2026
  91. Brinkmann OA, Bruns F, Prott FJ, Hertle L. Possible synergy of radiotherapy and chemo-immunotherapy in metastatic renal cell carcinoma (RCC). Anticancer Research. 1999;19:1583–1587
  92. Recchia F, Sica G, DeFilippis S. Chemo-immunotherapy in advanced head and neck cancer. Anticancer Research. 1999;19:773–778
  93. Aversa SM, Cattelan AM, Salvagno L. Chemo-immunotherapy of advanced AIDS-related Kaposi's sarcoma. Tumori. 1999;85:54–59
  94. Fukushima M. Adjuvant therapy of gastric cancer: the Japanese experience. Sem Oncol. 1996;23:369–378
  95. Fuchimoto S, Okamura S, Sato K, Orita K. Intratumoral injection of a streptococcal preparation, OK-432, before surgery for gastric cancer: A randomized trial. Cooperative study group of preoperative intratumoral immunotherapy for cancer. Cancer. 1994;74:3097–3103
  96. Aoyagi K, Koufuji K, Yano S. Unresectable advanced gastric cancer effectively treated by combined chemo-immunotherapy: a report of two cases. Kurume Medical Journal. 2000;47:177–182
  97. Arinaga S, Karimine N, Takamuku K. A trial of adjuvant chemoimmunotherapy with mitomycin C and OK-432 for stage III gastric carcinoma. J Surg Oncol. 1992;50:187–189
  98. Palmeri S, Meli M, Danova M. 5-Fluorouracil plus interferon alpha-2a compared to 5-fluorouracil alone in the treatment of advanced colon carcinoma: a multicentric randomized study. J Cancer Res Clin Oncol. 1998;124:191–198
  99. Faradji A, Bohbot A, Damonte J. A randomized study of combined 5-fluorouracil and plasma perfusion over protein A-sepharose in human advanced colorectal carcinoma. Biother. 1990;2:87–94
  100. Yang JC, Shlasko E, Ritchey JL. Combination chemoimmunotherapy for metastatic colorectal cancer using 5-fluorouracil, leucovorin, and interleukin-2. Eur J Cancer. 1993;29A:355–359
  101. Heys SD, Eremin D, Ruggeri EM. A phase III study of recombinant interleukin-2, 5-fluorouracil, and leucovorin versus 5-fluorouracil and leucovorin in patients with unresectable or metastatic colorectal carcinoma. Eur J Cancer. 1995;31A:19–25
  102. Colleoni M, Buzzoni R, Bajetta E. A phase II study of mitoxantrone combined with interferon-beta in unresectable hepatocellular carcinoma. Cancer. 1993;72:3196–3201
  103. Garaci E, Lopez M, Bonsignore G. Sequential chemoimmunotherapy for advanced non-small cell lung cancer using cisplatin, etoposide, thymosin-alpha 1 and interferon-alpha 2a. Eur J Cancer. 1995;31A:2403–2405
  104. Chao TY, Hwang WS, Yang MJ. Combination chemoimmunotherapy with interferon-alpha and cisplatin in patients with advanced non-small cell lung cancer. Chung Hua i Hsueh Tsa Chih – Chinese Med J. 1995;56:232–238
  105. Raitanen MP, Lukkarinen O. A controlled study of intravesical epirubicin with or without alpha 2b-interferon as prophylaxis for recurrent superficial transitional cell carcinoma of the bladder. Finnish Multicentre Study Group. British J Urology. 1995;76:697–701
  106. Ferrari P, Castagnetti G, Pollastri CA. Chemoimmunotherapy for prophylaxis of recurrence in superficial bladder cancer: interferon-alpha 2b versus interferon-alpha 2b with epirubicin. Anti-Cancer Drugs. 1992;3:25–27
  107. Uekado Y, Hirano A, Shinka T, Ohkawa T. The effects of intravesical chemoimmunotherapy with epirubicin and bacillus Calmette-Guerin for prophylaxis of recurrence of superficial bladder cancer: a preliminary report. Cancer Chemother Pharmacol. 1994;35:S65–S68
  108. Soulie P, Ruffie P, Trandafir L. Combined systemic chemoimmunotherapy in advanced diffuse malignant mesothelioma. Report of a phase I-II study of weekly cisplatin/interferon-alpha-2a. J Clin Oncol. 1996;14:878–885
  109. Fizazi K, Caliandro R, Soulie P. Combination raltitrexed (Tomudex(R))-oxaliplatin: a step forward in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesothelioma. Eur J Cancer. 2000;36:1514–1521
  110. Halme M, Knuuttila A, Vehmas T. High-dose methotrexate in combination with interferons in the treatment of malignant pleural mesothelioma. British J Cancer. 1999;80:1781–1785
  111. Le Cesne A, Vassal G, Farace F. Combination interleukin-2 and doxorubicin in advanced adult solid tumors: circumvention of doxorubicin resistance in soft-tissue sarcoma?. J Immunother. 1999;22:268–277
  112. Ota K, Ogawa N. Randomized controlled study of chemoimmunotherapy with bestatin of acute nonlymphocytic leukemia in adults. Biomed Pharmacother. 1990;44:93–101
  113. Kato M, Azuma E, Ido M. Ten-year survey of the intellectual deficits in children with acute lymphoblastic leukemia receiving chemoimmunotherapy. Med Ped Oncol. 1993;21:435–440
  114. Ophir R, Pecht M, Keisari Y. Thymic humoral factor-gamma 2 (THF-gamma 2) immunotherapy reduces the metastatic load and restores immunocompetence in 3LL tumor-bearing mice receiving anticancer chemotherapy. Immunopharm Immunotox. 1996;18:209–236
  115. Rashid G, Ophir R, Pecht M. Inhibition of murine Lewis lung carcinoma metastases by combined chemotherapy and intranasal THF-gamma 2 immunotherapy. J Immunother Tumor Immunol. 1996;19:324–333
  116. Asao T, Shibata HR, Batist G, Brodt P. Eradication of hepatic metastases of carcinoma H-59 by combination chemoimmunotherapy with liposomal muramyl tripeptide phosphatidylethanolamine, 5-fluoroucil, and leucovorin. Cancer Research. 1992;52:6254–6257
  117. Garaci E, Mastino A, Pica F, Favalli C. Combination treatment using thymosin alpha 1 and interferon after cyclophosphamide is able to cure Lewis lung carcinoma in mice. Cancer Immunol Immunother. 1990;32:154–160
  118. Ehrke MJ, Verstovsek S, Zaleskis G. Specific anti-EL4-lymphoma immunity in mice cured 2 years earlier with doxorubicin and interleukin-2. Cancer Immuno Immunother. 1996;42:221–230
  119. Ehrke MJ, Verstovsek S, Krawczyk CM. Cyclophosphamide plus tumor necrosis factor-alpha chemoimmunotherapy cured mice: life-long immunity and rejection of re-implanted primary lymphoma. Int J Cancer. 1995;63:463–471
  120. Zaleskis G, Ho RL, Diegelman P. Intracellular doxorubicin kinetics in lymphoma cells and lymphocytes infiltrating the tumor area in vivo:a flow cytometric study. Oncol Res. 1994;6:183–194
  121. Lumsden AJ, Codde JP, Gray BN, Van der Meide PH. Prevention of myelosuppression does not improve the therapeutic efficacy of chemoimmunotherapy. Anticancer Research. 1992;12:1725–1729
  122. Lumsden AJ, Codde JP, Gray BN. Influence of schedule on the therapeutic efficacy of chemoimmunotherapy with doxirubicin and interleukin-2. Biother. 1992;5:113–118
  123. Daemen T, Dontje BH, Regts J, Scherphof GL. Chemoimmunotherapy of murine liver metastases with 5-fluorouracil in combination with liposome-encapsulated muramyl dipeptide. J Immunother. 1993;13:31–35
  124. Silecchia G, Guarino E, Sinibaldi-Vallebona P. Efficacy of repeated cycles of chemo-immunotherapy with thymosin alpha1 and interleukin-2 after intraperitoneal 5-fluorouracil delivery. Cancer Immunol Immunother. 1999;48:172–178
  125. Iigo M, Tsuda H, Moriyama M. Enhanced therapeutic effects of anti-tumor agents against growth and metastases of colon carcinoma 26 when given in combination with interferon and interleukin-2. Clin Exp Metastasis. 1994;12:368–374
  126. Kusnierczyk H, Pajtasz-Piasecka E, Radzikowski C. Synergistic antitumour effects of chemo-immunotherapy with an oxazaphosphorine drug and IL-2-secreting cells in a mouse colon cancer model. Medical Oncology. 1999;16:267–278
  127. Iida S, Matsuoka S, Kudo C. Combination chemo-immunotherapy of murine solid tumor with OK-432, G-CSF, IL-2, and chemotherapeutics. Int J Immunopharm. 1995;17:973–980
  128. Hamuro J, Kikuchi T, Takatsuki F, Suzuki M. Cancer cell progression and chemoimmunotherapy–dual effects in the induction of resistance to therapy. British J Cancer. 1996;73:465–471
  129. Garaci E, Pica F, Mastino A. Antitumor effect of thymosin alpha 1/interleukin-2 or thymosin alpha 1/interferon alpha,beta following cyclophosphamide in mice injected with highly metastatic Friend erythroleukemia cells. J Immunother. 1993;13:7–17
  130. Farone AL, Cox DC. 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)/interleukin-2 chemoimmunotherapy of murine L1210 leukemia. Cancer Immunol Immunother. 1992;34:279–281
  131. Zagozdzon R, Golab J, Stoklosa T. Effective chemo-immunotherapy of L1210 leukemia in vivo using interleukin-12 combined with doxorubicin but not with cyclophosphamide, paclitaxel or cisplatin. Int J Cancer. 1998;77:720–727
  132. Zagozdzon R, Golab J, Mucha K, Foroncewicz B, Jakobisiak M. Potentiation of antitumor effects of IL-12 in combination with paclitaxel in murine melanoma model in vivo. Int J Molc Med. 1999;4:645–648
  133. Golab J, Zagozdzon R, Kozar K. Potentiatied anti-tumor effectiveness of combined therapy with interleukin-12 and mitoxantrone of L1210 leukemia in vivo. Oncology Reports. 2000;7:177–181
  134. Taylor DD, Gercel-Taylor C, Fowler WC, Weese JL. Enhancement of antitumor effects of combined chemoimmunotherapy. J Immunother. 1993;13:91–97
  135. Salup RR, Sicker DC, Wolmark N, Herberman RB, Hakala TR. Chemoimmunotherapy of metastatic murine renal cell carcinoma using flavone acetic acid and interleukin-2. J Urology. 1992;147:1120–1123
  136. Zagozdzon R, Stoklosa T, Golab J. Augmented antitumor effects of combination therapy with interleukin-12, cisplatin, and tumor necrosis factor-alpha in a murine melanoma model. Anticancer Research. 1997;17:4493–4498
  137. Pica F, Fraschetti M, Matteucci C, Tuthill C, Rasi G. High doses of thymosin alpha 1 enhance the anti-tumor efficacy of combination chemo-immunotherapy for murine B16 melanoma. Anticancer Research. 1998;18:3571–3578
  138. Sampath P, Hanes J, DiMeco F. Paracrine immunotherapy with interleukin-2 and local chemotherapy is synergistic in the treatment of experimental brain tumors. Cancer Research. 1999;59:2107–2114
  139. Acerbis G, Cleris L, Rodolfo M, Parmiani G, Formelli F. Postsurgical adjuvant chemoimmunotherapy with recombinant interleukin-2 and 1,3-bis-(2-chloroethyl)-1-nitrosourea on spontaneous metastases of a non-immunogenic murine tumor. Cancer Immunol Immunother. 1992;34:383–388
  140. Tzai TS, Lin JS, Chow NH. Effects of chemoimmunotherapy with and without surgery in murine MBT-2 bladder tumor. Urologia Internationalis. 1994;53:6–11
  141. Leonard MP, Gearhart JP, Jeffs RD. Chemoimmunotherapy in conjunction with surgery: strategies for management of murine neuroblastoma. J Ped Surg. 1991;26:1224–1229
  142. Kruse CA, Beck LT. Artificial-capillary-system development of human alloreactive cytotoxic T-lymphocytes that lyse brain tumours. Biotechnol Appl Biochem. 1997;25:197–205
  143. Kruse CA, Cepeda L, Owens B. Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and Interleukin-2. Cancer Immunol Immunother. 1997;45:77–87
  144. Rosenberg SA, Packard BS, Aebersold PM. Use oftumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma, a special report. N Eng J Med. 1988;319:1676–1680
  145. Rosenberg SA. Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens. J Nat Cancer Inst. 1996;88:1635–1644
  146. Paul DB, Kruse CA. Immunological approaches for the therapy of brain tumors. Current Neurology and Neuroscience Reports. 2001;1:238–244
  147. Elias EG, Suter CM, Fabian DS. Adjuvant immunotherapy in melanoma with irradiated autologous tumor cells and low dose cyclophosphamide. J Surg Oncol. 1997;64:17–22
  148. Plautz GE, Miller DW, Barnett GH. T cell adoptive immunotherapy of newly diagnosed gliomas. Clin Cancer Research. 2000;6:2209–2218
  149. Kroger MJ, Menzel T, Gschwend JE, Bergmann L. Life quality of patients with metastatic renal cell carcinoma and chemo-immunotherapy – a pilot study. Anticancer Research. 1999;19:1553–1555
  150. Yamano Y, Yoshimura A, Shibuya M, Kudoh S. Combined effect of adoptive immunotherapy (AIT) with lymphokine-activated killer (LAK) cells and interleukin-2 (IL-2) and chemotherapy in tumor-bearing mice. Nippon Ika Daigaku Zasshi - Journal of the Nippon Medical School. 1997;64:211–219

PII: S0305-7372(01)90222-1

doi: 10.1053/ctrv.2001.0222

Cancer Treatment Reviews
Volume 27, Issue 6 , Pages 375-402 , December 2001

Article Tools